Progressive supranuclear palsy

Wakabayashi K, Hansen LA, Vincent I, Mallory M, Masliah E. Neurofibrillary tangles in the dentate granule cells of patients with Alzheimer s disease, Lewy body disease and progressive supranuclear palsy. Acta Neuropathol Berl 1997 93 7-12. 

Henderson J., Carpenter K., Cartwright H., Halliday G. (2000a). Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson s disease clinical and therapeutic implications. Brain 123(7), 1410-21. 

They include progressive supranuclear palsy, corticobasal degeneration and Pick s disease 753... 

TABLE 45-2 Tau diseases Alzheimer s disease Down s syndrome Progressive supranuclear palsy Corticobasal degeneration Pick s disease Argyrophilic grain disease Tangle-only dementia... 

The study of FTDP-17 has established that dysfunction or misregulation of tau protein can cause neurodegeneration and dementia. It follows that tau protein is probably also of central importance in the pathogenesis of diseases, such as Alzheimer s disease, progressive supranuclear palsy, corticobasal degeneration and Pick s disease. This is further underlined by the fact that the aforementioned diseases are partially or completely phenocopied by cases of FTDP-17. 

OSN olfactory sensory neuron PSP progressive supranuclear palsy... 

Other progressive neurologic disorders that affect components of frontal-subcortical circuits (e.g., postencephalitic Parkinson s disease, neuroacanthocytosis, progressive supranuclear palsy, and Huntington s disease) also can present with OCD symptoms (Cum-... 

Perry T. L., Hansen S., and Jones K. (1988). Brain amino acids and glutathione in progressive supranuclear palsy. Neurology 38 943-946. 

Rascol O, Sieradzan K, Peyro-Saint-Paul H, Thalamas C, Brefel-Courbon C, Senard JM, Ladure P, Montastruc JL, Lees A (1998) Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov. Disord. 13 673-676. 

Three patients had improvements in dystonia and parkinsonism after taking zolpidem 10 mg (12). The improvement in dystonia began at 15-45 minutes and optimal benefits were observed after 1-2 hours. The mean duration of action was 4.5 hours initially, falling to 2-3 hours with chronic use. This is similar to that reported in patients with progressive supranuclear palsy, and corresponds to the drug s half-life (2.5 hours). Sleepiness was noted at doses over 10 mg bd. 

In a double-blind, placebo-controlled, crossover study, 10 patients with probable progressive supranuclear palsy took single oral doses of zolpidem (5 and 10 mg), co-... 

Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999 341(7) 543-4. 

Schrag A, Ben-Shlomo Y, Quinn NP (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy a cross-sectional study. Lancet 354 1771-1775... 

Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, Hutton M, Standaert DG, Vonsattel JP, Gibson GE, Beal ME (2000) Frontal lobe dysfunction in progressive supranuclear palsy evidence for oxidative stress and mitochondrial impairment. J Neurochem 74(2) 878-881... 

Capatros-Lefebvre D, Seigeant N, Lees A, Camuzat A, Daniel S, Lannuzel A et al (2002) Guadeloupean parkinsonism a cluster of progressive supranuclear palsy-Uke tauopathy. Brain 125 801-811... 

---